Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Evaluation of Residual Anti-Xa Activity As A Function Of Time Following The Last Treatment Dose of Enoxaparin In Patients Presenting For Elective Surgery

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03296033
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:32.982244+00:00
Published At
2023-10-05T00:00:00+00:00
Record Updated At
2023-10-05
Results Posted At
2023-10-05
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Anticoagulants and Bleeding Disorders", "Surgery", "Regional Anesthesia Morbidity"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-10-05"
protocolSection.identificationModule.nctId
"NCT03296033"
protocolSection.identificationModule.officialTitle
"Evaluation of Residual Anti-Xa Activity As A Function Of Time Following The Last Treatment Dose of Enoxaparin In Patients Presenting For Elective Surgery"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-10-05"

Study condition terms

  • Anticoagulants and Bleeding Disorders (protocolSection.conditionsModule.conditions)
  • Surgery (protocolSection.conditionsModule.conditions)
  • Regional Anesthesia Morbidity (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.